Bita Sahaf
Stanford University
Publications 59
#1Bita Sahaf (Stanford University)H-Index: 14
#2Adeeb Rahman (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 16
Last.Sean C. Bendall (Stanford University)H-Index: 31
view all 4 authors...
#1Jed Paul (Stanford University)H-Index: 1
#2Hideki NakasoneH-Index: 17
Last.David B. Miklos (Stanford University)H-Index: 30
view all 13 authors...
Chronic graft- versus -host disease (cGvHD) limits the effectiveness of hematopoietic cell transplantation (HCT) and often leads to significant morbidity and non-relapse mortality.[1][1] We have previously shown that antibodies targeting Y-chromosome encoded proteins (HY antibodies) detected at 3-
1 CitationsSource
#1Felix J. Hartmann (Stanford University)H-Index: 10
#2Joel Babdor (UCSF: University of California, San Francisco)H-Index: 4
Last.Sean C. Bendall (Stanford University)H-Index: 31
view all 14 authors...
Summary The success of immunotherapy has led to a myriad of clinical trials accompanied by efforts to gain mechanistic insight and identify predictive signatures for personalization. However, many immune monitoring technologies face investigator bias, missing unanticipated cellular responses in limited clinical material. We present here a mass cytometry (CyTOF) workflow for standardized, systems-level biomarker discovery in immunotherapy trials. To broadly enumerate immune cell identity and acti...
2 CitationsSource
#1Everett MeyerH-Index: 20
#2Ginna G. LaportH-Index: 25
Last.Robert N. NegrinH-Index: 79
view all 21 authors...
#1Zinaida GoodH-Index: 5
#2Luciene Borges (Stanford University)H-Index: 10
Last.Sean C. Bendall (Stanford University)H-Index: 31
view all 8 authors...
Selective differentiation of naive T cells into multipotent T cells is of great interest clinically for the generation of cell-based cancer immunotherapies. Cellular differentiation depends crucially on division state and time. Here we adapt a dye dilution assay for tracking cell proliferative history through mass cytometry and uncouple division, time and regulatory protein expression in single naive human T cells during their activation and expansion in a complex ex vivo milieu. Using 23 marker...
5 CitationsSource
#1Richard E. Frye (UA: University of Arizona)H-Index: 37
#2James P. Andrus (Lucile Packard Children's Hospital)
Last.Leonore A. Herzenberg (Stanford University)H-Index: 93
view all 23 authors...
Besides understanding the effectiveness of N-acetylcysteine (NAC) for the treatment of disease and its effect on physiological systems, other considerations of NAC are important, including the pharmacology, formulations, and adverse effects of NAC. This chapter will review these important aspects of NAC. Few published trials have examined the pharmacokinetics of NAC. Maximum plasma concentration increases with oral NAC doses (up to 1200 mg has been studied), particularly with sustained-release f...
#1Pietro Ghezzi (BSMS: Brighton and Sussex Medical School)H-Index: 73
#2Kevin V. Lemley (Stanford University)H-Index: 31
Last.Leonore A. Herzenberg (Stanford University)H-Index: 93
view all 23 authors...
Glutathione (GSH) deficiency may play a pivotal role in a variety of apparently unrelated clinical conditions and diseases. Orally administered N-acetylcysteine (NAC), which replenishes the cysteine required for GSH synthesis, has been tested in a large number of randomized placebo-controlled trials involving these diseases and conditions. This chapter focused on developing a base of evidence suggesting that NAC administration improves disease by increasing cysteine and/or GSH in a variety of di...
#1Nasheed Mohammad Hossain (Stanford University)H-Index: 5
#2Bita Sahaf (Stanford University)H-Index: 14
Last.David B. Miklos (Stanford University)H-Index: 30
view all 18 authors...
Autologous CD19 directed CAR T-cell therapy has response rates of >70% in adult acute lymphoblastic leukemia (ALL) and >40% in adult diffuse large B cell lymphoma (DLBCL). Large trials (ZUMA-1/JULIET/TRANSCEND) have highlighted that many patients fail to achieve durable responses. Several groups have reported on the phenomenon of CD19 immune escape as a cause (Grupp et al, NEJM 2013, Neelapu et al, NEJM 2017) and the NIH Pediatric Oncology Branch has shown CD22 as an alternative target (Fry et a...
9 CitationsSource
#1Liora M. Schultz (Stanford University)H-Index: 4
#2Kara L. Davis (Stanford University)H-Index: 11
Last.Crystall L. Mackall (Stanford University)H-Index: 69
view all 15 authors...
Chimeric Antigen Receptor (CAR) therapy targeting CD19 achieves complete remission (CR) rates of 70%-90% in relapsed/refractory B-ALL. Relapse due to loss of the CD19 targeted epitope presents a therapeutic challenge as evidenced by the largest global pediatric CD19-CAR experience which showed 15 of 16 relapses to be explained by CD19 downregulation (Maude et al, NEJM 2018). Alternatively targeting CD22 using CD22-CAR therapy has demonstrated a CR rate of approximately 70% in both CD19+ and CD19...
9 CitationsSource
#1Jay Y. Spiegel (Stanford University)H-Index: 2
#2Bita Sahaf (Stanford University)H-Index: 14
Last.David B. Miklos (Stanford University)H-Index: 30
view all 24 authors...
Background: Axicabtagene ciloleucel (axi-cel), an autologous anti-CD19 chimeric antigen receptor (CAR-T), showed significant clinical responses in patients with relapsed-refractory large-B cell lymphomas in the Zuma-1 trial (Neelapu et al, NEJM 2017). Zuma-1 analysis showed blood CAR-T cell expansion was associated with clinical response and toxicity. Herein, we report on 25 patients treated with commercial axi-cel and describe CAR-T expansion by immunophenotyping and its correlation with clinic...